Special News: Arrowhead Research Corp (NASDAQ:ARWR), Amgen Inc. (NASDAQ:AMGN), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Lakeway, NY — (MARKET NEWS CALL) — 10/16/2014— Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Arrowhead Research Corp (NASDAQ:ARWR), Amgen Inc. (NASDAQ:AMGN), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).
Arrowhead Research Corp (NASDAQ:ARWR)’s shares gained 10.03% to $6.47. Glancy Binkow & Goldberg LLP, representing investors of Arrowhead Research Corporation, on Oct. 14 has filed a class action lawsuit in the United States District Court for the Central District of California on behalf of a class comprising purchasers of Arrowhead common stock between Aug. 12, 2014 and Oct. 8, 2014, inclusive. The Complaint alleges that defendants made false and/or misleading statements and failed to disclose material adverse facts about ARWR’s operations and financial prospects. Specifically, defendants misrepresented the true viral reduction level that ARC-520 can induce in humans, and failed to disclose that data from the Phase IIa study of ARC-520 did not support their assertions concerning the drug’s ability to induce a certain reduction level of hepatitis B surface antigens in humans.
Amgen Inc. (NASDAQ:AMGN)’s shares dropped 0.98% to $130.90. The company on Oct. 9 announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow.1 As part of the acceptance, the FDA granted blinatumomab priority review with a Prescription Drug User Fee Act (PDUFA) action date of May 19, 2015.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s shares climbed 5.80% to $3.83. Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) on Oct. 13 announced that data from the Phase 3 clinical trial program for BELVIQ (lorcaserin HCl) CIV will be presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting taking place Oct. 12-15, 2014, in Austin, Texas. BELVIQ is a serotonin 2C receptor agonist approved in the United States as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m2 or greater (obese), or BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes.
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in Specialpennystockalert.com. PLEASE always do your own due diligence, and consult your financial advisor.
Tags: Amgen Inc. (NASDAQ:AMGN), Arena Pharmaceuticals, Arrowhead Research Corp (NASDAQ:ARWR), Inc. (NASDAQ:ARNA)